Upregulation of NRG-1 and VAMP-1 in human brain aggregates exposed to clozapine

Schizophrenia Research

Volumn 113, Issue 2-3, 2009, Pages 273-276

  Chana, Gursharan ^a   Lucero, Ginger ^a   Salaria, Shahid ^a   Lozach, Jean ^b   Du, Pinyi ^c   Woelk, Christopher ^c   Everall, Ian ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Aggregates; Clozapine; Haloperidol; NRG 1; Synaptic; VAMP 1

Indexed keywords

CLOZAPINE; HALOPERIDOL; MESSENGER RNA; NEU DIFFERENTIATION FACTOR; SYNAPTOBREVIN 1; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN TISSUE; NERVE CELL; NORMAL VALUE; PRIORITY JOURNAL; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SYNAPTIC EFFICACY; UPREGULATION;

ANTIPSYCHOTIC AGENTS; BRAIN; CLOZAPINE; FETUS; HALOPERIDOL; HUMANS; NEUREGULIN-1; UP-REGULATION; VESICLE-ASSOCIATED MEMBRANE PROTEIN 1;

EID: 68049142991     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.05.015     Document Type: Article

References (34)

1. Barros C.S., Calabrese B., Chamero P., Roberts A.J., Korzus E., Lloyd K., et al. Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system. Proc Natl Acad Sci U S A. (2009)
2. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162 (1987) 156-159
3. Corradini I., Verderio C., Sala M., Wilson M.C., and Matteoli M. SNAP-25 in neuropsychiatric disorders. Ann N Y Acad Sci 1152 (2009) 93-99
4. Critchlow H.M., Maycox P.R., Skepper J.N., and Krylova O. Clozapine and haloperidol differentially regulate dendritic spine formation and synaptogenesis in rat hippocampal neurons. Mol Cell Neurosci 32 (2006) 356-365
5. Eastwood S.L., and Harrison P.J. Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons. Schizophr Res 73 (2005) 159-172
6. Eastwood S.L., and Harrison P.J. Cellular basis of reduced cortical reelin expression in schizophrenia. Am J Psychiatry 163 (2006) 540-542
7. Facciola G., Avenoso A., Scordo M.G., Madia A.G., Ventimiglia A., Perucca E., et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders. Ther Drug Monit 21 (1999) 341-345
8. Fatemi S.H., Earle J.A., Stary J.M., Lee S., and Sedgewick J. Altered levels of the synaptosomal associated protein SNAP-25 in hippocampus of subjects with mood disorders and schizophrenia. Neuroreport 12 (2001) 3257-3262
9. Halim N.D., Weickert C.S., McClintock B.W., Hyde T.M., Weinberger D.R., Kleinman J.E., et al. Presynaptic proteins in the prefrontal cortex of patients with schizophrenia and rats with abnormal prefrontal development. Mol Psychiatry 8 (2003) 797-810
10. Halim N.D., Weickert C.S., McClintock B.W., Weinberger D.R., and Lipska B.K. Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus. Neuropsychopharmacology 29 (2004) 1063-1069
11. Higgs B.W., Elashoff M., Richman S., and Barci B. An online database for brain disease research. BMC Genomics 7 (2006) 70
12. Honer W.G., and Young C.E. Presynaptic proteins and schizophrenia. Int Rev Neurobiol 59 (2004) 175-199
13. Kodama M., Fujioka T., and Duman R.S. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 56 (2004) 570-580
14. Kontkanen O., Toronen P., Lakso M., Wong G., and Castren E. Antipsychotic drug treatment induces differential gene expression in the rat cortex. J Neurochem 83 (2002) 1043-1053
15. Li D., Collier D.A., and He L. Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Hum Mol Genet 15 (2006) 1995-2002
16. Liu C.M., Hwu H.G., Fann C.S., Lin C.Y., Liu Y.L., Ou-Yang W.C., et al. Linkage evidence of schizophrenia to loci near neuregulin 1 gene on chromosome 8p21 in Taiwanese families. Am J Med Genet B Neuropsychiatr Genet 134 (2005) 79-83
17. Livak K.J., and Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods (San Diego, Calif 25 (2001) 402-408
18. Mei L., and Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 9 (2008) 437-452
19. Mukaetova-Ladinska E.B., Hurt J., Honer W.G., Harrington C.R., and Wischik C.M. Loss of synaptic but not cytoskeletal proteins in the cerebellum of chronic schizophrenics. Neurosci Lett 317 (2002) 161-165
20. Petryshen T.L., Middleton F.A., Kirby A., Aldinger K.A., Purcell S., Tahl A.R., et al. Support for involvement of neuregulin 1 in schizophrenia pathophysiology. Mol Psychiatry 10 (2005) 328
21. Roh, H.K., Chung, J.Y., Oh, D.Y., Park, C.S., Svensson, J.O., Dahl, M.L., et al. (2001): Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. 52:265-271.
22. Salaria S., Chana G., Caldara F., Feltrin E., Altieri M., Faggioni F., et al. Microarray analysis of cultured human brain aggregates following cortisol exposure: implications for cellular functions relevant to mood disorders. Neurobiol Dis (2006)
23. Sawada K., Barr A.M., Nakamura M., Arima K., Young C.E., Dwork A.J., et al. Hippocampal complexin proteins and cognitive dysfunction in schizophrenia. Arch Gen Psychiatry 62 (2005) 263-272
24. Scarr E., Gray L., Keriakous D., Robinson P.J., and Dean B. Increased levels of SNAP-25 and synaptophysin in the dorsolateral prefrontal cortex in bipolar I disorder. Bipolar Disord 8 (2006) 133-143
25. Sokolov B.P., Tcherepanov A.A., Haroutunian V., and Davis K.L. Levels of mRNAs encoding synaptic vesicle and synaptic plasma membrane proteins in the temporal cortex of elderly schizophrenic patients. Biol Psychiatry 48 (2000) 184-196
26. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71 (2002) 877-892
27. Stefansson H., Sarginson J., Kong A., Yates P., Steinthorsdottir V., Gudfinnsson E., et al. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet 72 (2003) 83-87
28. Thompson P.M., Egbufoama S., and Vawter M.P. SNAP-25 reduction in the hippocampus of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 411-417
29. Trillo-Pazos G., Kandanearatchi A., Eyeson J., King D., Vyakarnam A., and Everall I.P. Infection of stationary human brain aggregates with HIV-1 SF162 and IIIB results in transient neuronal damage and neurotoxicity. Neuropathol Appl Neurobiol 30 (2004) 136-147
30. Wang X.D., Su Y.A., Guo C.M., Yang Y., and Si T.M. Chronic antipsychotic drug administration alters the expression of neuregulin 1beta, ErbB2, ErbB3, and ErbB4 in the rat prefrontal cortex and hippocampus. Int J Neuropsychopharmacol 11 (2008) 553-561
31. Webster M.J., Shannon Weickert C., Herman M.M., Hyde T.M., and Kleinman J.E. Synaptophysin and GAP-43 mRNA levels in the hippocampus of subjects with schizophrenia. Schizophr Res 49 (2001) 89-98
32. Young C.E., Arima K., Xie J., Hu L., Beach T.G., Falkai P., et al. SNAP-25 deficit and hippocampal connectivity in schizophrenia. CerebCortex 8 (1998) 261-268
33. Zhang H.X., Zhao J.P., Lv L.X., Li W.Q., Xu L., Ouyang X., et al. Explorative study on the expression of neuregulin-1 gene in peripheral blood of schizophrenia. Neurosci Lett 438 (2008) 1-5
34. Zoccali R., Muscatello M.R., Torre D.L., Malara G., Canale A., Crucitti D., et al. Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacol Res 48 (2003) 411-414